Patrice P Cacoub

Summary

Country: France

Publications

  1. ncbi Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, France
    J Acquir Immune Defic Syndr 40:47-52. 2005
  2. ncbi Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate
    P Cacoub
    AP HP, Department of Internal Medicine, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013, Paris, France
    Osteoporos Int 24:1751-7. 2013
  3. ncbi Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection
    Benjamin Terrier
    Department of Internal Medicine, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    Rheumatology (Oxford) 51:2083-90. 2012
  4. ncbi [Kidney involvement in mixed cryoglobulinemia: which treatment?]
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, 75013 Paris, France
    Presse Med 41:254-9. 2012
  5. ncbi Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals
    Patrice Cacoub
    Department of Internal Medicine, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, and Universite Pierre et Marie Curie, Paris, France
    J Hepatol 56:455-63. 2012
  6. ncbi Application in general practice of treatment guidelines for patients with dyslipidaemia: the RESPECT study
    Patrice Cacoub
    Service Medecine Interne, Groupe Hospitalier La Pitié Salpêtrière, Universite Pierre et Marie Curie Paris VI, AP HP, 47, Boulevard de l Hopital, 75013 Paris, France
    Arch Cardiovasc Dis 101:715-21. 2008
  7. ncbi Prevalence of peripheral arterial disease in high-risk patients using ankle-brachial index in general practice: a cross-sectional study
    P Cacoub
    Pierre et Marie Curie, Paris 6, University, Paris, France
    Int J Clin Pract 63:63-70. 2009
  8. ncbi Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis
    D Saadoun
    Pierre et Marie Curie Paris 6, University 1, CNRS, UMR 7087, Paris, F 75013 France
    Ann Rheum Dis 67:1431-6. 2008
  9. ncbi [Systemic vasculitis due to hepatitis C virus]
    Patrice Cacoub
    Service de Medecine Interne, Hopital de la Pitie Salpetriere, 83, Boulevard de l Hopital, 75651 Cedex 13 Paris, France
    Bull Acad Natl Med 190:123-34; discussion 135-7. 2006
  10. ncbi Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry
    Patrice P Cacoub
    Pierre and Marie Curie University Paris 6, and AP HP, Hospital La Pitié Salpêtrière, Paris, France
    Atherosclerosis 204:e86-92. 2009

Detail Information

Publications95

  1. ncbi Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, France
    J Acquir Immune Defic Syndr 40:47-52. 2005
    ..To evaluate the incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy...
  2. ncbi Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate
    P Cacoub
    AP HP, Department of Internal Medicine, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013, Paris, France
    Osteoporos Int 24:1751-7. 2013
    ..Because DRESS is a severe drug reaction, the occurrence of a rash in a patient treated with strontium ranelate should lead to prompt and permanent treatment discontinuation...
  3. ncbi Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection
    Benjamin Terrier
    Department of Internal Medicine, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    Rheumatology (Oxford) 51:2083-90. 2012
    ..These findings suggest the potential multifaceted benefits of vitamin D supplementation in HCV-infected patients with extra-hepatic manifestations, but interventional studies are needed to confirm these data...
  4. ncbi [Kidney involvement in mixed cryoglobulinemia: which treatment?]
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, 75013 Paris, France
    Presse Med 41:254-9. 2012
    ..1/100 patient-years), particularly in patients over 70 years, with a renal insufficiency and previously treated with high dose steroids...
  5. ncbi Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals
    Patrice Cacoub
    Department of Internal Medicine, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, and Universite Pierre et Marie Curie, Paris, France
    J Hepatol 56:455-63. 2012
    ..In case of suspicion or confirmed diagnosis of SCAR, all study medication must be discontinued...
  6. ncbi Application in general practice of treatment guidelines for patients with dyslipidaemia: the RESPECT study
    Patrice Cacoub
    Service Medecine Interne, Groupe Hospitalier La Pitié Salpêtrière, Universite Pierre et Marie Curie Paris VI, AP HP, 47, Boulevard de l Hopital, 75013 Paris, France
    Arch Cardiovasc Dis 101:715-21. 2008
    ..The impact on general practitioners (GP) of the 2005 French guidelines for hypercholesterolaemia has not been evaluated...
  7. ncbi Prevalence of peripheral arterial disease in high-risk patients using ankle-brachial index in general practice: a cross-sectional study
    P Cacoub
    Pierre et Marie Curie, Paris 6, University, Paris, France
    Int J Clin Pract 63:63-70. 2009
    ..We evaluated the prevalence and predictive factors of PAD in high-risk patients using the ankle-brachial index (ABI)...
  8. ncbi Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis
    D Saadoun
    Pierre et Marie Curie Paris 6, University 1, CNRS, UMR 7087, Paris, F 75013 France
    Ann Rheum Dis 67:1431-6. 2008
    ..To report the results of a pilot study using rituximab combined with Peg-interferon (IFN) alpha2b-ribavirin in severe refractory hepatitis C virus (HCV) related mixed cryoglobulinaemia (MC) vasculitis...
  9. ncbi [Systemic vasculitis due to hepatitis C virus]
    Patrice Cacoub
    Service de Medecine Interne, Hopital de la Pitie Salpetriere, 83, Boulevard de l Hopital, 75651 Cedex 13 Paris, France
    Bull Acad Natl Med 190:123-34; discussion 135-7. 2006
    ..This article reviews the main diagnostic, pathophysiologic and therapeutic aspects of HCV-induced systemic vasculitis...
  10. ncbi Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry
    Patrice P Cacoub
    Pierre and Marie Curie University Paris 6, and AP HP, Hospital La Pitié Salpêtrière, Paris, France
    Atherosclerosis 204:e86-92. 2009
    ..To examine differences in risk factor (RF) management between peripheral artery disease (PAD) and coronary artery (CAD) or cerebrovascular disease (CVD), as well as the impact of RF control on major 1-year cardiovascular (CV) event rates...
  11. ncbi Hepatitis C virus infection induced vasculitis
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    Clin Rev Allergy Immunol 35:30-9. 2008
    ..For future prospects and projects, new therapeutic strategies include a combination of best antiviral treatment with Peg-Interferon plus Ribavirin and Rituximab. Multicenter controlled trials are mandatory...
  12. ncbi Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study
    Patrice Cacoub
    Department of Internal Medicine, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, Paris cedex 13 F 75651, France
    World J Gastroenterol 14:6195-203. 2008
    ....
  13. ncbi [HIV and hepatitis C virus coinfection]
    P Cacoub
    Service de Medecine Interne, AP HP, hôpital La Pitié Salpêtrière, 83, Bd de l Hopital, 7 5651 Paris cedex 13, France
    Gastroenterol Clin Biol 32:S82-9. 2008
    ..Effective management strategies that encompass patient and viral factors are necessary to improve the long-term outlook for coinfected patients...
  14. ncbi [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008]
    P Cacoub
    Service de Medecine Interne, AP HP, Hopital Pitie Salpetriere, 47 83, Boulevard de l Hopital, 75013 Paris, France
    Rev Med Interne 29:283-9. 2008
    ..FUTURE PROSPECTS AND PROJECTS: Individualized treatment for PAH should take into account the type of PAH, the comorbidities (liver disease), treatment interactions, and long-term efficacy...
  15. ncbi [Cryoglobulinemia]
    P Cacoub
    Service de Médecine Interne II, hôpital La Pitié Salpêtrière, AP HP, 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Rev Med Interne 29:200-8. 2008
    ..FUTURE PROSPECTS AND PROJECTS: New therapeutic strategies include a combination of best antiviral treatment with Peg-interferon-alpha plus ribavirin and rituximab. Multicenter controlled trials are mandatory...
  16. ncbi Hepatitis B-related autoimmune manifestations
    Patrice Cacoub
    Service de Medecine Interne, AP, HP Pitié Salpêtrière Hospital Group, 75651 Paris Cedex 13, France
    Rheum Dis Clin North Am 35:125-37. 2009
    ..Discussion of two hypotheses of the pathophysiology of the virus is followed by descriptions of the general, renal, rheumatologic, neurologic, skin, ophthalmologic, and hematologic manifestations...
  17. ncbi [Management of HCV-HIV and HBV-HIV coinfected patients]
    Patrice Cacoub
    , Paris 6, CNRS, UMR 7087, Paris, France
    Gastroenterol Clin Biol 31:887-94. 2007
  18. ncbi Patients with peripheral arterial disease in the CHARISMA trial
    Patrice P Cacoub
    Department of Internal Medicine, La Pitie Salpetriere Hospital, AP HP, 47 83 boulevard de l Hopital, F 75651 Paris Cedex 13, France
    Eur Heart J 30:192-201. 2009
    ..The aim of this study was to determine whether clopidogrel plus aspirin provides greater protection against major cardiovascular events than aspirin alone in patients with peripheral arterial disease (PAD)...
  19. ncbi Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    J Hepatol 48:35-42. 2008
    ..To analyze the barriers to HCV treatment in HIV-HCV co-infected patients and their evolution between 2004 and 2006...
  20. ncbi The DRESS syndrome: a literature review
    Patrice Cacoub
    Department of Internal Medicine, Pitie Salpetriere Hospital, Assistance Publique Hopitaux de Paris, France
    Am J Med 124:588-97. 2011
    ..The outcome was death in 9 cases. However, no predictive factors for serious cases were found. This better knowledge of DRESS may contribute to improve the diagnosis and management of this syndrome in clinical practice...
  21. ncbi Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe
    Patrice P Cacoub
    AP HP Service de Médecine Interne, Groupe Hospitalier La Pitié Salpêtrière, 47 83, Boulevard de l Hopital, 75013 Paris, France
    Heart 97:660-7. 2011
    ..To examine the impact of cardiovascular risk factor control on 3-year cardiovascular event rates in patients with stable symptomatic atherothrombotic disease in Europe...
  22. ncbi Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
    P Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    Ann Rheum Dis 67:283-7. 2008
    ..A relapse of cryoglobulinemia vasculitis was frequently noted. Randomised controlled trials with long-term study are needed to form definitive conclusions on the benefit/risk ratio of rituximab therapy in such patients...
  23. ncbi Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: modifications in three consecutive large surveys between 2004 and 2009
    Patrice Cacoub
    Universite Pierre et Marie Curie PARIS6, CNRS, UMR 7211, France
    J Hepatol 53:230-7. 2010
    ..To analyze the care of HCV infection in HIV-HCV coinfected patients and its progression between 2004 and 2009...
  24. ncbi Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    Antivir Ther 14:839-45. 2009
    ..The aim of this study was to assess the effect of insulin resistance (IR) on the response to hepatitis C virus (HCV) therapy in HIV-HCV-coinfected patients...
  25. ncbi Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C
    David Saadoun
    , , Paris, France
    Hepatology 43:1337-45. 2006
    ..001), and steatosis higher than 10% (P = .04). In conclusion, our study shows an independent association between cryoglobulin and steatosis as well as advanced fibrosis...
  26. ncbi Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy
    Dan Avi Landau
    Service de Medecine Interne, AP HP, Hopital Pitie Salpetriere, Paris, France
    J Rheumatol 37:615-21. 2010
    ..We studied causes of death and predictive factors in patients with HCV-associated MC vasculitis treated with antivirals...
  27. ncbi Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response
    Dan Avi Landau
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, Paris, France
    Arthritis Rheum 58:604-11. 2008
    ....
  28. ncbi Cryofibrinogenemia: new insights into clinical and pathogenic features
    David Saadoun
    Pierre et Marie Curie Paris 6 University, Department of Internal Medicine, Hopital Pitie Salpetriere, Paris, France
    Am J Med 122:1128-35. 2009
    ..Cryofibrinogenemia is an under-recognized cryoprotein that can be life-threatening when untreated. Our aim was to describe the prevalence and clinical findings of patients with cryofibrinogenemia and to clarify the mechanisms involved...
  29. ncbi [Treatment of extrahepatic manifestations associated with hepatitis C virus infection]
    Patrice Cacoub
    , , Paris
    Gastroenterol Clin Biol 26:B210-9. 2002
  30. ncbi Cryoglobulinaemia vasculitis in patients coinfected with HIV and hepatitis C virus
    David Saadoun
    , , Paris, France
    AIDS 20:871-7. 2006
    ..03). The clinical manifestations of MC vasculitis did not differ significantly between the two groups. CONCLUSION: There was a beneficial effect of anti-HCV therapy for HIV/HCV-coinfected patients with MC vasculitis...
  31. ncbi Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis
    Damien Sene
    Department of Internal Medicine, La Pitie Salpetriere Hospital, France
    Clin Biochem 39:715-21. 2006
    ..We assessed the reliability of non-invasive biological scoring indexes (Fibrotest-Actitest [FT-AT], Forns, APRI, age-platelet, platelet, hyaluronic acid) as non-invasive alternatives to liver biopsy (LB) in 138 HCV-infected patients...
  32. ncbi Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM V707, Paris, France
    AIDS 20:525-31. 2006
    ..To evaluate the prevalence and severity of steatosis and possible interactions between steatosis, host factors, viral factors, and treatment for HIV infection in HIV-hepatitis C virus (HCV) coinfected patients...
  33. ncbi Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis
    Dan Avi Landau
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    Arthritis Rheum 58:2897-907. 2008
    ..The aim of this study was to prospectively evaluate the evolution of this defect during the course of antiviral treatment...
  34. ncbi PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis
    Patrice Cacoub
    hôpital La Pitié Salpêtrière, Paris, France
    Arthritis Rheum 52:911-5. 2005
    ..The present trial was established to investigate the efficacy of therapy with PEGylated interferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin in patients with HCV-related MC vasculitis...
  35. ncbi Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN
    Laurent Alric
    Service de Medecine Interne, Pavillon Dieulafoy, CHU Purpan, Toulouse, France
    Am J Kidney Dis 43:617-23. 2004
    ..The influence of hepatitis C virus (HCV) treatment on the course of HCV cryoglobulinemic membranoproliferative glomerulonephritis (MPGN) is controversial...
  36. ncbi Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial
    Fabrice Carrat
    Groupe Hospitalier Universitaire Est, , INSERM U444, Paris, France
    JAMA 292:2839-48. 2004
    ..CONCLUSION: In combination with ribavirin, treatment with peginterferon alfa-2b is more effective than standard interferon alfa-2b for HCV infection in HIV-infected patients...
  37. ncbi Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia
    David Saadoun
    Department of Internal Medicine, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Blood 116:326-34; quiz 504-5. 2010
    ..Our findings indicate that rituximab combined with Peg-IFN-alpha/ribavirin is well tolerated and more effective than Peg-IFN-alpha/ribavirin in HCV-MC...
  38. ncbi Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection
    Laurent Alric
    Service de Medecine Interne, Pavillon Dieulafoy, CHU Purpan, Toulouse, France
    Gastroenterology 123:1494-9. 2002
    ....
  39. ncbi Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients
    Benjamin Terrier
    Department of Internal Medicine, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris AP HP, CNRS UMR 7211, and Université Pierre et Marie Curie Paris 6, Paris, France
    Arthritis Rheum 60:2531-40. 2009
    ..To report on the long-term followup of a cohort of patients with hepatitis C virus (HCV)-related vasculitis treated with rituximab with or without PEGylated interferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin...
  40. ncbi Cryoglobulinemia vasculitis
    Patrice Cacoub
    Service de Medecine Interne, hôpital La Pitié Salpêtrière, Paris, France
    Curr Opin Rheumatol 14:29-35. 2002
    ....
  41. ncbi Treatment of hepatitis C in HIV/hepatitis C co-infected patients: what is the evidence?
    Patrice Cacoub
    Department of Internal Medicine, hôpital La Pitié Salpêtrière, 41 Boulevard de l hôpital, 75013 Paris, France
    Int J STD AIDS 16:1-4. 2005
    ..Furthermore, in about half the patients, treatments were not stopped during the first months of treatment because of side effects, but due to non-early virological response...
  42. ncbi Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study
    David Saadoun
    , Paris, France
    Arthritis Rheum 54:3696-706. 2006
    ..CONCLUSION: PEG-IFN alfa-2b plus ribavirin should be considered as induction therapy for HCV-MC vasculitis. An early virologic response and the absence of renal insufficiency are the key factors in the clinical response...
  43. ncbi Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment
    Firouzé Bani-Sadr
    INSERM U707, Faculte de Medecine Hopital Saint Antoine, Paris, France
    Clin Infect Dis 41:1806-9. 2005
    ..02), and elevated total bilirubin level (OR, 7.9; 95% CI, 1.08-93.3; P<.03). Didanosine should thus not be given to patients with cirrhosis, particularly when treatments for HCV and HIV infections have to be administered concomitantly...
  44. ncbi Hepatitis C virus infection in systemic lupus erythematosus: a case-control study
    Gabriel Perlemuter
    , , , Paris, France
    J Rheumatol 30:1473-8. 2003
    ..HCV infection has moderate signs of biochemical and liver pathological severity. SLE by itself or treated with steroids does not seem to worsen HCV infection...
  45. ncbi Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis
    Patrice Cacoub
    Department of Internal Medicine, hôpital La Pitié Salpêtrière, Paris, France
    Arthritis Rheum 46:3317-26. 2002
    ..Therefore, we retrospectively analyzed the response to treatment in patients with chronic hepatitis C complicated by systemic vasculitis who had received antiviral therapy with interferon-alpha (IFNalpha) and ribavirin...
  46. ncbi Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis
    David Saadoun
    Université Pierre et Marie Curie Paris, Paris, France and Hôpital Pitié Salpêtrière, Service de Medecine Interne, Paris, France
    Curr Opin Rheumatol 20:23-8. 2008
    ..This review focuses on recent advances in our understanding of the treatment of hepatitis C virus-mixed cryoglobulinemia vasculitis...
  47. ncbi Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    J Hepatol 48:765-73. 2008
    ..To compare non-invasive biological liver fibrosis scores, as alternatives to liver biopsy, in HIV/HCV co-infected patients...
  48. ncbi How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited
    Jerome Lambert
    Université Pierre et Marie Curie Paris INSERM, UMR S 707 unité de santé publique, Assistance Publique Hopitaux de Paris, Hopital Saint Antoine, Paris, France
    Clin Chem 54:1372-8. 2008
    ..We explored other fibrosis staging accuracy measures designed for ordinal gold standards, the C-statistic and the Obuchowski measure...
  49. ncbi Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis
    David Saadoun
    , , , 75013 Paris, France
    J Hepatol 41:1031-7. 2004
    ..This enhanced production of type-1 cytokines may account for a more severe course of liver disease...
  50. ncbi Hepatitis C virus-associated extrahepatic manifestations: a review
    Damien Sene
    Department of Internal Medicine, Boulevard de l Hopital, Paris, France
    Metab Brain Dis 19:357-81. 2004
    ..Howerver, even in cases of tight association, the mechanisms through which HCV may promote or induce extrahepatic manifestations remain unclear and merit further investigations...
  51. ncbi Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection
    Olivier Hermine
    Department of Hematology and Centre National de la Recherche Scientifique Unité Mixte de Recherche 8603, Hopital Necker, Paris, France
    N Engl J Med 347:89-94. 2002
    ..We undertook this study after a patient with splenic lymphoma with villous lymphocytes had a hematologic response after antiviral treatment of HCV infection...
  52. ncbi Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus
    Damien Sene
    Department of Internal Medicine, , Paris, France
    J Rheumatol 31:2199-206. 2004
    ..Symptomatic persistent HCV MC was associated with advanced age, longer duration of HCV infection, type II MC, and a higher MC serum level...
  53. ncbi Screening of unrecognized peripheral arterial disease (PAD) using ankle-brachial index in high cardiovascular risk patients free from symptomatic PAD
    Jean Jacques Mourad
    Department of Internal Medicine, Avicenne University Hospital AP HP and Paris 13 University, Bobigny, France
    J Vasc Surg 50:572-80. 2009
    ..Although PAD is a consistent predictor of cardiovascular morbidity and mortality, it is often under-diagnosed and under-treated...
  54. ncbi Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection
    Marie Matignon
    Nephrology and Transplantation Department, Henri Mondor Hospital, AP HP, Institut Francilien de Recherche en Néphrologie et Transplantation and Paris XII University, Creteil, France
    Medicine (Baltimore) 88:341-8. 2009
    ..These findings emphasize the need for repetitive clinical evaluation in those patients...
  55. ncbi Hepatitis C virus infection and mixed cryoglobulinaemia vasculitis: a review of neurological complications
    Patrice Cacoub
    Department of Internal Medicine, hôpital La Pitié Salpêtrière, Paris, France
    AIDS 19:S128-34. 2005
    ..Central nervous system (CNS) involvement is more rarely reported. In this review, peripheral and CNS involvement associated with chronic HCV infection are described. The underlying mechanisms and treatment possibilities are discussed...
  56. ncbi Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study
    Dominique Salmon-Ceron
    Infectious Diseases, Internal Medicine Department, Hopital Cochin, Universite Paris Descartes, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
    J Hepatol 50:736-45. 2009
    ..We describe the proportion of liver-related deaths among HIV-infected patients in 2005 compared with 2000...
  57. ncbi Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C
    Valerie Touitou
    Department of Ophthalmology, Pitie Salpetriere Hospital, Paris, France
    Am J Ophthalmol 140:949-52. 2005
    ..To report the cases of four patients with hepatitis C virus infection who experienced clinical features that are virtually identical to Vogt-Koyanagi-Harada disease (VKH)...
  58. ncbi Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study
    Patrick Marcellin
    Department of Hepatology, University of Paris 7, INSERM U 773, CRB3, Beaujon Hospital, Clichy, France
    Liver Int 31:516-24. 2011
    ..Adherence is important for therapy of chronic diseases, but has still not been well studied in real life in chronic hepatitis C...
  59. ncbi A new presentation of neonatal lupus: 5 cases of isolated mild endocardial fibroelastosis associated with maternal Anti-SSA/Ro and Anti-SSB/La antibodies
    Gaëlle Guettrot-Imbert
    AP HP, Service de Medecine Interne, Centre de Référence National pour le Lupus Systémique et le Syndrome des Antiphospholipides, Centre Hospitalier Universitaire Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    J Rheumatol 38:378-86. 2011
    ..These points, considered in association with 5 unusual cases of mild EFE, led us to consider the relationship between underrecognized cases of isolated autoantibody-associated EFE and DCM that had been considered idiopathic...
  60. ncbi [Management of HCV-HIV patients]
    Stanislas Pol
    Unité d Hépatologie, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris
    Gastroenterol Clin Biol 31:4S7-12. 2007
    ..The harmful impact of HIV underlines the need for improving:..
  61. ncbi Vasculitides associated with malignancies: analysis of sixty patients
    Olivier Fain
    Assistance Publique Hopitaux de Paris, Hopital Jean Verdier, Universite Paris, Bondy, France
    Arthritis Rheum 57:1473-80. 2007
    ..To describe characteristics and outcomes of vasculitides associated with malignancies...
  62. ncbi Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus
    Nathalie Costedoat-Chalumeau
    Assistance Publique Hopitaux de Paris, Centre Hospitalier Universitaire Pitie Salpetriere, Universite Paris VI Pierre et Marie Curie, Paris, France
    Arthritis Rheum 54:3284-90. 2006
    ..To study the possible relationship between whole-blood hydroxychloroquine (HCQ) concentrations and clinical efficacy of HCQ in patients with systemic lupus erythematosus (SLE)...
  63. ncbi Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study
    Jacques Blacher
    Hotel Dieu Hospital, Universite Paris Descartes, Faculte de Medecine, AP HP, Paris, France
    J Vasc Surg 44:314-8. 2006
    ..Despite the increased cardiovascular morbidity and mortality risk of patients with peripheral arterial disease, previous worldwide studies have documented undertreatment of cardiovascular risk factors in such patients...
  64. ncbi Leiomyosarcoma of the inferior vena cava: experience in 22 cases
    Edouard Kieffer
    Department of Vascular Surgery, Pitie Salpetriere University Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Ann Surg 244:289-95. 2006
    ..Although surgical resection combined with chemotherapy is usually not curative, it can achieve reasonably long-term survival. We recommend aggressive operative management using the latest vascular surgery and oncology techniques...
  65. ncbi Peripheral neuropathies associated with primary Sjögren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy
    Damien Sene
    Service de Medecine Interne, AP HP, Hopital Pitie Salpetriere, and Université Pierre et Marie Curie Paris 6, Paris, France
    Medicine (Baltimore) 90:133-8. 2011
    ....
  66. ncbi Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?
    David Saadoun
    Department of Hematology, Hopital Necker, Paris, France
    Blood 105:74-6. 2005
    ..This study underscores the role of HCV in the lymphomagenesis and the benefit of antiviral treatment for patients presenting with HCV-driven lymphoproliferations...
  67. ncbi Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease
    Sophie Hue
    Laboratory of Immunology, Hopital Necker, Paris, France
    J Infect Dis 186:106-9. 2002
    ..HLA class II alleles may weakly contribute to the severity of HCV liver disease. Of persons infected with HCV, only 15%-20% spontaneously clear the virus, and the rest become chronically infected...
  68. ncbi Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C
    Patrice Cacoub
    Department of Internal Medicine, hôpital La Pitié Salpêtrière, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    J Hepatol 36:812-8. 2002
    ..The aim was to assess the prevalence of these symptoms prior to any treatment, and on prolonged follow-up in treated and untreated patients...
  69. ncbi CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis
    Olivier Boyer
    , CNRS/UPMC, , , Paris, France
    Blood 103:3428-30. 2004
    ....
  70. ncbi Hepatitis B virus genotypes and extrahepatic manifestations
    Patrice Cacoub
    Department of Internal Medicine, hôpital La Pitié Salpêtrière, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    J Hepatol 43:764-70. 2005
    ..This study aimed at correlating the presence of extrahepatic manifestations with hepatitis B virus (HBV) genotypes in patients with chronic HBV infection...
  71. ncbi Kidney diseases in HIV/HCV-co-infected patients
    Hassane Izzedine
    Departments of Nephrology, Pitie Salpetriere Hospital, Paris, France
    AIDS 23:1219-26. 2009
    ..Hepatitis C virus (HCV) co-infection occurs in 25% of HIV-infected persons. The impact of HIV/HCV coinfection on renal and patient outcomes is unclear...
  72. ncbi Cryofibrinogen in patients with hepatitis C virus infection
    Aurelien Delluc
    Service de Medecine Interne, Universite Pierre et Marie Curie, Paris 6, France
    Am J Med 121:624-31. 2008
    ..The objective was to study the prevalence and the clinical and therapeutic impacts of cryofibrinogen in HCV-infected patients...
  73. ncbi High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U707, Paris, France
    AIDS 21:1645-8. 2007
    ..Antiretroviral therapy in general was independently associated with lower HCV viral load. This suggests that HCV viral load kinetics could differ according to the choice of HAART regimen...
  74. ncbi Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C
    Damien Sene
    Department of Internal Medicine, Hopital Pitie Salpetriere, Paris, France
    World J Gastroenterol 13:3137-40. 2007
    ..Rare as they are, such severe ophthalmological complications require a close follow-up of HCV-infected patients under IFN-alpha treatment with ophthalmological monitoring if any ocular manifestation occurs...
  75. ncbi Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia
    David Saadoun
    Department of Internal Medicine, , Paris, France
    Arch Intern Med 166:2101-8. 2006
    ..06) and renal involvement (OR, 5.20) were independently associated with death. CONCLUSION: Patients with non-HCV-related MC vasculitis have a poor outcome and have a 4-fold increased risk of developing B-cell NHL...
  76. ncbi Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword?
    Valerie Touitou
    Department of Ophthalmology, Pitie Salpetriere Hospital, University of Paris VI, 47 83 boulevard de l Hopital, 75013 Paris, France
    Int Ophthalmol 27:211-5. 2007
    ..We report a small case series of two patients with refractory Vogt-Koyanagi-Harada disease, treated with interferon-alpha and discuss the potential benefits or detrimental role of interferon therapy in these patients...
  77. ncbi Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection
    Michal Abel
    INSERM, U561 Equipe AVENIR, Paris, France
    Hepatology 44:1607-16. 2006
    ..Therapeutic modulation of the intrahepatic balance between specific and bystander CD8 T cells might be beneficial in patients with chronic hepatitis C...
  78. ncbi Systemic vasculitis in patients with hepatitis C virus infection with and without detectable mixed cryoglobulinemia
    Benjamin Terrier
    Department of Internal Medicine, APHP Groupe Hospitalier Pitié Salpétrière, 47 Boulevard de l Hopital, 75013 Paris, France
    J Rheumatol 38:104-10. 2011
    ..to describe hepatitis C virus (HCV)-related systemic vasculitis in patients without detectable mixed cryoglobulinemia (MC) and to compare them to typical cases of HCV-MC vasculitis...
  79. ncbi Prevalence and clinical significance of cryofibrinogenaemia in patients with renal disorders
    Benjamin Terrier
    Department of Internal Medicine, Groupe Hospitalier Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
    Nephrol Dial Transplant 26:3577-81. 2011
    ..In patients with end-stage renal disease, thromboses are common. However, the implication of CryoFg was never assessed. The aim of this study is to describe the prevalence and the significance of CryoFg in patients with renal disorders...
  80. ncbi Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)
    Lionel Piroth
    Service de Maladies Infectieuses et Tropicales, CHU Dijon, 10 boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon Cedex, France
    AIDS 21:1323-31. 2007
    ..To describe the characteristics of hepatitis B (HBV) infection in HIV-infected patients and the impact of anti-HBV treatments...
  81. ncbi Care of patients with hepatitis C and HIV co-infection
    Vincent Soriano
    AIDS 18:1-12. 2004
  82. ncbi Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1982-8. 2007
    ..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)...
  83. ncbi Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?
    Firouzé Bani-Sadr
    J Acquir Immune Defic Syndr 45:123-5. 2007
  84. ncbi Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients
    Christopher Payan
    Départment de Microbiologie EA3882, CHU Hôpital Morvan, Brest, France
    Gut 56:1111-6. 2007
    ....
  85. ncbi Vascular cell adhesion molecule-1 (VCAM-1) plays a central role in the pathogenesis of severe forms of vasculitis due to hepatitis C-associated mixed cryoglobulinemia
    Gilles Kaplanski
    INSERM U387, Hopital Sainte Marguerite, 270 boulevard Sainte Marguerite, 13009 Marseille, France
    J Hepatol 42:334-40. 2005
    ..To better characterize the molecules involved in leukocyte tissue infiltration during hepatitis C-mixed cryoglobulinemia (HCV-MC)-associated vasculitis...
  86. ncbi Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)
    Eric Rosenthal
    , , Nice, France
    AIDS 17:1803-9. 2003
    ..CONCLUSIONS: In the post-HAART era, ESLD due to HCV is a growing cause of mortality in HIV-infected patients. Increased longevity attributable to HAART, and a higher prevalence of alcohol consumption, are probably involved in this trend...
  87. ncbi Serum alpha-fetoprotein predicts virologic response to hepatitis C treatment in HIV coinfected patients
    Fabrice Carrat
    UPMC Paris6, UMR S707, INSERM, UMR S707, Saint Antoine Hospital, Assistance Publique Hopitaux de Paris, France
    AIDS 22:1513-5. 2008
    ..83; 95% confidence interval 1.05-3.20). Serum alpha-fetoprotein measurement should be integrated in the pretreatment assessment of prognostic factors of a virologic response...
  88. ncbi Treatment with Peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia
    David Saadoun
    J Hepatol 43:737; author reply 738. 2005
  89. ncbi Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin
    Firouzé Bani-Sadr
    AIDS 22:1385-7. 2008
  90. ncbi Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay
    Philippe Halfon
    Laboratoire Alphabio, 23 Rue de Friedland, Hopital Ambroise Pare, 13006 Marseille, France
    J Clin Microbiol 46:2106-8. 2008
    ..The significance of such occult infection must be elucidated...
  91. ncbi Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis
    David Saadoun
    Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, Centre National de Recherche Université Pierre et Marie Curie, Unité Médicale de Recherche 7087, Paris, France
    Blood 111:5334-41. 2008
    ..01). Our findings indicate that in patients with MC, response to B-cell depletion induced by rituximab effectively normalizes many of the disturbances in peripheral B- and T-lymphocyte homeostasis...
  92. ncbi [The diagnostic tools of hepatitis C virus infections]
    Philippe Halfon
    Departement de Virologie, Laboratoire Alphabio, Marseille
    Presse Med 33:538-41. 2004
    ..The latter is useful in selecting the right therapy and duration of treatment, because the response depends on the genotype (better response rate for the genotypes 2 and 3)...
  93. ncbi Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U707, France
    Clin Infect Dis 46:768-74. 2008
    ..We determined the prevalence and determinants of worsening fibrosis in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who were receiving anti-HCV therapy...
  94. ncbi [Noninvasive methods for predicting liver fibrosis in patients with chronic hepatitis C: alternatives to liver biopsy]
    Philippe Halfon
    Laboratoire Alphabio, Marseille
    Presse Med 36:457-66. 2007
    ....
  95. ncbi Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel
    Vincent Soriano
    AIDS 16:813-28. 2002